NASH (non-alcoholic steatohepatitis) is a liver disorder characterized by accumulation of fat in the liver and liver scarring. It occurs most commonly in patients with obesity and is often associated with diabetes. Without treatment, NASH can progress rapidly to cirrhosis, liver failure, and even liver cancer. Distinguishing NASH from other liver disorders and identifying high-risk patients is challenging. To help clinicians identify and optimally treat patients with NASH, Rockpointe and the Potomac Center for Medical Education offer a free CME/ABIM MOC activity in a live webinar format.
Beyond diagnosis, a lack of effective, FDA-approved treatment options has limited clinicians’ ability to treat NASH patients, with lifestyle management and supportive care remaining the primary treatment modalities. In recent years, however, several novel agents have emerged as potential treatment options, backed by promising clinical safety and efficacy data. New Advances in the Diagnosis and Management of NASH is an hour-long online continuing medical education course that will provide gastroenterologists and hepatologists with the latest information on how to screen for, diagnose, and risk-stratify NASH and how to develop patient-personalized multidisciplinary treatment plans. Clinicians will also learn about novel agents in development for NASH, the clinical trial data supporting their use, and how best to integrate these agents into clinical practice as they become available.
Dates and times
Thursday, March 31, 2022
7:00 – 8:00 PM ET (6:00 – 7:00 PM CT / 4:00 – 5:00 PM PT)
Tuesday, April 12, 2022
5:30 – 6:30 PM ET (4:30 – 5:30 PM CT / 2:30 – 3:30 PM PT)
Tuesday, May 10, 2022
6:00 – 7:00 PM CT (7:00 – 8:00 PM ET/ 4:00 – 5:00 PM PT)
Wednesday, November 2, 2022
7:00 – 8:00 PM ET (6:00 – 7:00 PM CT / 4:00 – 5:00 PM PT)
This activity is intended for gastroenterologists, hepatologists, and other clinicians who treat patients with NASH. At its conclusion, participants should be able to:
- Utilize current guideline-recommended strategies for the diagnosis and risk stratification of patients with NASH.
- Develop personalized, multidisciplinary treatment plans for patients with NASH.
- Assess the safety and efficacy of emerging therapies for the treatment of NASH.
This program is CME-certified and ABIM MOC-eligible and qualifies the participant for 1 hour of credit. There is no fee for this activity, which is supported by an educational grant from Novo Nordisk and is jointly provided by the Potomac Center for Medical Education (PCME) and Rockpointe. Full accreditation information will be provided to participants prior to starting the course.
Through effective accredited continuing education, Rockpointe, a leader in educational programming with more than 26 years of experience, strives to improve and advance the quality of patient care. Its educational programs have been at the forefront of new issues in healthcare, including implementing MIPS, combatting the nation’s opioid and COVID-19 crises, recognizing issues with vaping, and utilizing technical advances in care. Sign up for Rockpointe’s CME course catalog and view a list of current educational opportunities, including on-demand webcourse offerings and live webinars, at www.rockpointe.com.
As part of its commitment to quality, Rockpointe works to inform the continuing-education community of significant quality-improvement issues through news and analysis on Policy & Medicine, which offers a daily look at legal, regulatory, and compliance issues affecting the pharmaceutical and device industry. Rockpointe also publishes Policy & Medicine Compliance Update, a monthly publication that provides a concise update on compliance issues facing the life science industry and goes in-depth into important cases, laws, and regulations in straightforward articles. At Rockpointe, education equals quality.
To register for New Advances in the Diagnosis and Management of NASH, click here.